Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The University of Texas Health Science Center at San Antonio
This is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and associated nail toxicities. The therapeutic intervention will involve patients wearing an Elasto-Gel cold glove and sock on one hand and one foot (both on the right side or both on the left side). The patients will wear the glove and sock during each infusion of taxane chemotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of early stage breast cancer (stage I-III).
Planned to receive treatment with either adjuvant or neo-adjuvant taxane-based chemotherapy.
Age \> 18 years. There is no upper age limit for participation in this study.
Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation.
Prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs)
All patients will have given signed, informed consent prior to registration
Patients must have a performance status of ECOG 0 or 1.
You may not be if
Patients must not have received any prior taxane or platinum based chemotherapy.
Patients must not have a history of peripheral neuropathy (regardless of cause).
Patient must not have a history of Raynaud's disease.
Patients with partial or complete limb amputations.
Known hypersensitivity to cold
Patient cannot be on the following medications: GABA analogues (such as Neurontin, lyrica), tricyclic antidepressants (such as amitriptyline or nortriptyline)
As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements.
Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial
